|jonwig - I never bought back in, fortunately, I made money during the dual listing episode so facied another bite at the cherry.
I had similar concerns to you, but couldn't understand why they kept buying things and developing new products if they hand no money, well its history now, even if they are rescued the inner circle of shareholders and creditors will exact a huge price.
I'm sure many of the management teams of these small companies actually engineer a company failure so that they can pick up the pieces and make themselves rich; its done so many times and the buyer usually appears almost from nowhere within hours or a couple of days.
I detest the weak British company law that allows so many manager to walk away from companies they have ruined with their pockets full.
Maybe I'm being harsh, but we'll see soon, best you luck to all.
All IMO, DYOR|
|AAAInvestment - I do hope you managed to escape from this dog before today. As pointed out four years ago:
jonwig - 9 Mar'06 - 12:10 - 139 of 217 edit
This loan note business and the need for periodic repayments is the main reason (by far) why I kept away from this company post-FLT: there would have been little prospect of bottom-line earnings whilst it was in place, and possibly cashflow problems on top.....
That was always the elephant hiding behind the sofa.
The old Flintstone days were great fun and made some of us a fair amount of money, but that was then and I doubt these sort of fairy stories will come round again any time soon.|
|I bought into this when the Euro listing occured, I was one of the last purchasers at the old price and made a nice profit of a few hundred pounds when I sold up.
However, I liked the companies product line then and still do, on the face of it they have good products and established routes to market.
The problem for me is that I'm no expert and would appreciate anyones views on if the so-called revolutionary products work?, are they ahead of the competition?, is there a real market? and why are customers not snapping them up if they are so good?
I first looked at this company after reading an article (FT I think) which suggested it was a high risk tiddler to watch, well I've watched and little has happened except a collapse in SP, but still have a sneaky suspicion that it could be a winner - any thoughts?|
|Proventec Raises 1.5m
News story from Growth Company Investor
|It started rising when the share was quoted in Europe as well as on AIM. I wonder if some European investrs know something that we don't?|
|Big move up these last few weeks. Last broker target I had was for 14p - cicra 280p after the conversion.
Intriguing sub-£20 million plays
Other intriguing businesses priced at sub-£20 million include steam-cleaning and coatings technology group Proventec, which recently secured a potentially highly lucrative 14-month tender (with the option for a one-year extension) to provide steam-cleaning equipment to the NHS, as part of the battle against hospital-acquired infections.
Results for the half to September were highly encouraging, revealing a fourfold revenue rise to £5.8 million and a threefold profits surge to £391,000. With analysts pencilling in 40 per cent profits growth for the current year, the 7.25p shares could rise in more favourable markets|
|Mention of proventec here. About the euronext listing.
Does anyone know if this would make PROV eligible for an ISA?|
|Midas Tip 31/1/2008
Epic code: PROV (Aim)
Closing price (30/01/2008): 7.63p
Our second stock this week is Proventec, a company that has devised a way to make hospitals and factories cleaner than they ever knew it was possible to be. The group makes steam cleaning equipment that manages to be environmentally friendly and incredibly efficient, killing bacteria so effectively that is has been scientifically ratified.
The device is used by food companies in the UK and Europe and the company has just been awarded a 14-month tender by the NHS for the sole provision of specialist steam cleaning equipment. This does not mean that hospitals have to use Proventec's kit but it certainly encourages them to do so. Indeed one of the major benefits of these cleaning machines is that they can kill the superbug MRSA stone dead while patients are still lying in their beds.
Other devices use bleach and other noxious substances so powerful that wards have to be emptied while they are cleaned. Proventec only uses steam so patients are not harmed even as their wards become germ-free and sparkling.
The machines also tick the environmental box because they use far less water than conventional cleaning. One litre of water produces up to 2,000 litres of steam so, instead of filling up endless buckets to mop floors and wash walls, the steam machine does the job with the same amount of water as you would get in a large jug.
The technology is under consideration by a number of hospitals in the UK but up to 1,000 could benefit from it. Proventec also believes there will be huge demand abroad, particularly in the US and Japan. The company is small at the moment but it is already profitable, delivering turnover of almost £5m last year and underlying earnings of £2.3m. By 2009, turnover is expected virtually to double and profits should grow substantially too.
Midas verdict: Dirty hospitals are a recurrent theme in the UK and Proventec has found a way to combat the problem. A recent investor was so impressed with the technology that she bought a machine for her home and says it has never been cleaner! Proventec shares are trading at 7.63p but brokers believe it is worth nearer 14p. This stock is not hugely liquid but it is worth tracking down the shares and holding on. The price should rise significantly.
Proventec: Latest share charts, news archive, other share tips, director dealing and much more...
Proventec - SPECULATIVE BUY
("Proventec" or "the Company")
Award of NHS Tender
Proventec (AIM:PROV), a provider of specialist steam cleaning technologies, announces that it has been awarded a 14-month tender for the sole provision of specialist steam cleaning equipment by the National Health Service ("NHS") Purchase and Supply Agency.
The tender agreement, won by Osprey DeepClean ("Osprey"), the Company's wholly owned subsidiary, is a direct response to the UK Government's £50 million of extra funding for the Strategic Health Authority. The agreement has an option of a further one year extension.
David Chestnutt, Chief Executive of Proventec, said: "This is a significant contract for Proventec and rewards the Company for its commitment to innovation and problem solving. Proventec has undertaken an eighteen month programme of product development and rigorous microbiological performance trials with University College London Hospitals (UCLH) resulting in purpose designed steam cleaning tools for hospital equipment cleaning that can help combat the 'superbug' epidemic. The NHS Trusts have recognised the benefits of our technology and we are already starting to see strong demand convert into orders".
"Hospitals have a duty of care to provide a clean environment for patients. There have been accusations that the Government's recent initiative for a national deep clean is merely a gimmick. It is not. Rather, it is a long awaited overhaul of all UK NHS Trusts. However, it is not enough unless future ongoing cleaning regimes are prioritised and upheld. Patients everywhere deserve wards that are cleaned regularly and thoroughly, it is only through this process that we will break the cycle of hospital-acquired infections."
Conventional deep cleaning of hospitals traditionally has involved emptying wards to enable staff to carry out comprehensive decontamination. Osprey's dry saturated steam cleaning machines and cleaning methodology can be used to rid all areas of micro-organisms, including 'superbugs' such as MRSA and Clostridium difficile, without compromising safety and without the need to remove patients.
Osprey's machines have been designed to be used to decontaminate wards and clean patient equipment on a daily basis in order to maintain high standards of hygiene. The Company has applied for patents on its specialist tooling enabling staff to clean all areas of the hospital including; mattresses, curtains and bed frames as well as walls and floor, without the use of antimicrobial chemicals that may contribute to microbial resistance.
David Chestnutt, Chief Executive of Proventec, added: "Through working through the 'Science of Healthcare Cleaning' with guidance from Infection control professionals within NHS hospitals and equipment suppliers, we have set new standards for hospital hygiene and redefined 'clean'. Our unique steam equipment is the only validated technology that has the full data to substantiate that we can achieve a viable method of surface disinfection, to support proactive infection prevention and control, yet which allows patients to remain on the wards."
Proventec continues to invest in market development. Osprey Steam Products and cleaning technique are currently in the final stages of scientific validation at TNO, Zeist, Netherlands, designed to set new Pan-European and Pan-American standards for microbiological decontamination of surfaces with dry steam vapour.
Furthermore, Osprey continues to collaborate with original equipment manufacturers of patient beds and equipment to confirm compatibility of Osprey's steam vapour cleaning with their products and materials and that the procedure does not infringe upon warranty standards or conditions.|
|A quote from the halfyearly results of Innoconcepts:
Proventec PLC, in which InnoConcepts holds a 38% interest, reported strong results over the financial year ending 30 March 2007. Net profit increased by 128% to more than GBP 1 million. At least as important was the completion this spring of the acquisition of an 80% interest in Contico Manufacturing Limited in Redruth, UK. Contico is one of the oldest and most prominent English distributors and producers in the field of cleaning products. The acquisition gives Proventec as a group a greater critical mass, and what is more the company saw a considerable increase in its international effectiveness. Proventec is expected to continue to grow in the coming period, both through organic growth and through acquisitions. Point of focus is the (still) limited liquidity of the share, which is listed on AIM, and thus the limited access to institutional investors. Together with InnoConcepts, Proventec is now studying options to improve this situation, partly in order to further facilitate its future growth by using its stock exchange listing.
Yes, you are right. I'm still dreaming.|
|lol! dream on...|
|The company does not have to raise new money. They need to issue shares because some ex-employee decided to exercise his options. 600.000 shares is next to nothing compared to the total number of outstanding shares: 243,404,855.
It may still take a couple of years but we'll be rewarded for our patience. I believe in their strategy. Moreover Inno-concepts still has a large share in Proventec. It has an excellent trackrecord in The Netherlands. In my opinion the valuation at 14p/share is at least a realistic one. For some information about Inno-concepts, have a look at:
Kind regards and all the best,
OnnoBass, The Netherlands|
|So having valued FLT shareholders holdings at 14p/share
a couple of years ago (reverse takeover), the company
finally hits the buffers and has to raise new money
at... 6p/share. Quite pitiful...|
|Someone is buying as you can sell 100K online|
|Yup - that, too!|
|Avoid. Run by cowboys...|
|Hi, PUG - yes, earnings per share are low and they are issuing too many shares.
No asset backing, which usually I'm keen to have.|
|Still valued (assuming I have doenmy sums correctly) at some 5x turnover. Seems far too high. Any thoughts?|
|Still holding although its been hard to justify|
|Thanks for that information, OnnoBass.
You're absolutely correct in saying that "The market for hygienic solutions, for example in the health- and food industry offers considerable possibilities for growth in the coming years."
But most earlier followers here of PROV are doubtful as to the slice it can take.
There aren't many holders left, here, unfortunately I think.|
|The recent rise may be caused by the positive outlook Innoconcepts (holds 39% of the shares of Proventec) published yesterday (with the presentation of their annual statements).
They said Proventec will invest the revenues from the sale of non core activities in acquisitions, autonomous growth and technological innovation.
In the past period expansion was realised in the US, Canada, France and the Benelux. The market for hygienic solutions, for example in the health- and food industry offers considerable possibilities for growth in the coming years.
I'm keeping my shares for the long term.
Have a good weekend,
OnnoBass (The Netherlands)|
|12 month low . Thick fog - minimal visability|
|This is an utter dog.
I invested in FLT not some bloody cleaning company. Should have bailed out at the changeover.|